Dr Reddy's to market three more Amgen products in India

The drugs provide treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis

Dr Reddy's Laboratories Limited announced today that it has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of collaboration, Dr Reddy's will commercialise XGeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in the country.

In 2015, Dr Reddy's had announced a marketing collaboration with Amgen to execute a full range of regulatory and commercial services, to seek approval of and launch of Amgen's Kyprolis (carfilzomib), Blincyto(blinatumomab) and Repatha (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr Reddy's deep understanding of patent and physician needs in the country, according to the company.

 

M V Ramana, executive vice president and head of emerging markets and India business at Dr Reddy's said,"We are delighted to continue our relationship with Amgen as it strengthens our constant endeavor to enhance patient's success to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis."